Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 2/20 | 0.41 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4364295 | 0.83 | BRD4 (0.55) | BRD4KMT2APOLBCYP2D6CYP2C9 | |
| SCHEMBL17792927 | 0.76 | POLB (0.42) | BRD4KMT2AMEN1ALDH1A1POLB | |
| SCHEMBL1954816 | 0.74 | P2RX4 (0.47) | ADORA3P2RX4KMT2AMEN1BCHE | |
| SCHEMBL28092692 | 0.72 | ADORA3 (0.48) | ADORA3BRD4P2RX4KMT2AMEN1 | |
| SCHEMBL13444609 | 0.70 | ALDH1A1 (0.54) | BRD4KMT2AMEN1ALDH1A1POLB | |
| SCHEMBL9183671 | 0.65 | P2RX4 (0.53) | ADORA3P2RX4KMT2AMEN1BCHE | |
| SCHEMBL5585204 | 0.65 | NOTUM (0.67) | KMT2AMEN1ALDH1A1POLB | |
| SCHEMBL30721522 | 0.65 | NOTUM (0.67) | KMT2AMEN1ALDH1A1POLB | |
| Bicarbonate SCHEMBL26677806 | 0.64 | BRD4 (0.44) | BRD4KMT2AMEN1POLB | |
| SCHEMBL6226194 | 0.64 | P2RX4 (0.47) | ADORA3P2RX4KMT2AMEN1BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7645784-B2 | Benzimidazole derivatives | ASTRAZENECA AB (SE) | 2010-01-12 | — | — | US | disclosed |
| US-20060287377-A1 | New benzimidazole derivatives | ASTRAZENECA AB (SE) | 2006-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287377-A1 | New benzimidazole derivatives | CYP2C9, CDK9, CCNI | ADORA3 854/4885BRD4 103/4885P2RX4 1006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.